Lesions of the cholinergic basal forebrain (CBF) system in animals using an immunotoxin produce robust behavioral deficits and mimic some aspects of Alzheimer's disease (AD). This model is useful for testing both the role of acetylcholine in cognitive processes and new therapeutic strategies such as gene therapy. The ability to control gene expression is an important requirement of this technology for clinical application. The vector systems being explored in this proposal may be exogenously regulated. This proposal will investigate mechanisms of restoring neurotransmitter function in animals with CBF immunotoxin lesions by 1) enhancing ACh release postgrafting via choline supplementation, and 2) transplanting cells capable of repressing or inducing the transgene for choline acetyltransferase (ChAT). The repressible system (tetracycline), and the inducible system (eccdysteroid), modulates gene expression of ChAT in a rapid, reversible and highly specific fashion. In the first series of experiments, the investigators will determine whether different doses of exogenously administered choline can augment the production and release of acetylcholine from genetically engineered fibroblasts grafted to the cortex and hippocampus of rats following immunotoxic lesions of the CBF. Once an increase in release has been determined, behavioral effects of this augmented release will be determined. For the second and third series of experiments, they will use the regulatable cell lines that either induce or repress ChAT expression after administration of doxycycline or Muristerone A, respectively. In their immunotoxin lesion they will demonstrate that acetylcholine released from these cells after grafting to the neocortex and hippocampus is both necessary and sufficient for behavioral recovery. The effects of these regulatable genes will be tested in a spatial and non-spatial task after determining the dose and duration of the exogenous compound needed to induce or repress gene expression. If successful, the experiments will demonstrate that release of ACh can be exogenously controlled in animals and results in significant behavioral improvement. The control of transmitter release is necessary before grafting or direct gene insertion experiments can be entertained in humans in order to be able to safely terminate delivery of the gene product. These approaches will not only be applicable for AD, but other neurodegenerative disorders and for delivering other transgenes of interest.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Research Project (R01)
Project #
5R01AG017533-05
Application #
6783320
Study Section
Special Emphasis Panel (ZRG1-BDCN-4 (01))
Program Officer
Buckholtz, Neil
Project Start
2000-09-01
Project End
2006-08-31
Budget Start
2004-09-01
Budget End
2006-08-31
Support Year
5
Fiscal Year
2004
Total Cost
$298,879
Indirect Cost
Name
Veterans Medical Research Fdn/San Diego
Department
Type
DUNS #
933863508
City
San Diego
State
CA
Country
United States
Zip Code
92161
Martin, Peter; Kliegel, Matthias; Rott, Christoph et al. (2008) Age differences and changes of coping behavior in three age groups: findings from the Georgia Centenarian Study. Int J Aging Hum Dev 66:97-114
Frielingsdorf, Helena; Simpson, Daniel R; Thal, Leon J et al. (2007) Nerve growth factor promotes survival of new neurons in the adult hippocampus. Neurobiol Dis 26:47-55
Frielingsdorf, Helena; Thal, Leon J; Pizzo, Donald P (2006) The septohippocampal cholinergic system and spatial working memory in the Morris water maze. Behav Brain Res 168:37-46
Pizzo, Donald P; Coufal, Nicole G; Lortie, Mark J et al. (2006) Regulatable acetylcholine-producing fibroblasts enhance cognitive performance. Mol Ther 13:175-82
Pizzo, Donald P; Paban, Veronique; Coufal, Nicole G et al. (2004) Long-term production of choline acetyltransferase in the CNS after transplantation of fibroblasts modified with a regulatable vector. Brain Res Mol Brain Res 126:1-13
Pizzo, D P; Thal, L J (2004) Intraparenchymal nerve growth factor improves behavioral deficits while minimizing the adverse effects of intracerebroventricular delivery. Neuroscience 124:743-55
Brandon, Eugene P; Mellott, Tiffany; Pizzo, Donald P et al. (2004) Choline transporter 1 maintains cholinergic function in choline acetyltransferase haploinsufficiency. J Neurosci 24:5459-66
Power, Ann E; Thal, Leon J; McGaugh, James L (2002) Lesions of the nucleus basalis magnocellularis induced by 192 IgG-saporin block memory enhancement with posttraining norepinephrine in the basolateral amygdala. Proc Natl Acad Sci U S A 99:2315-9